SeraCare Life Sciences Company Profile

Background

Founded in 1984, SeraCare Life Sciences has been a trusted partner and worldwide supplier to the diagnostic testing industry for over 30 years. The company specializes in advancing the development of clinical genomics, molecular, and serological diagnostics by providing innovative technologies, quality controls, reagents, and biological materials. As an ISO 13485-certified manufacturer, SeraCare is committed to ensuring the accuracy and safety of diagnostic results, thereby supporting the promise of precision medicine.

Key Strategic Focus

SeraCare's strategic focus centers on delivering high-quality diagnostic products and services that support emerging test methods. The company offers a comprehensive portfolio, including:

• NGS Reference Standards: Multiplexed clinical genomics reference standards for applications such as tumor profiling, non-invasive prenatal testing (NIPT), cell-free DNA, and germline sequencing.

• Infectious Disease Assay Tools: Serological and molecular quality controls and panels to validate, monitor, and ensure confidence in assay performance.

• Immunoassay Reagents: Antibodies and immunoassay reagents to support research and in vitro diagnostic assay development.

• Assay Developer OEM Solutions: Customizable biological materials to help diagnostic assay developers build more robust assays.

• NGS Controls for Cancer Profiling Assays: Reference materials with clinically relevant DNA and RNA variants for NGS and PCR-based tests.

• Human Blood Fractions: Purified blood-based proteins, including human serum albumin and human gamma globulin, for use in controls, calibrators, diluents, and buffer formulations.

These offerings are designed to expedite development, improve robustness, and better characterize NGS-based assays, thereby ensuring optimal assay performance and compliance.

Financials and Funding

As of May 2025, SeraCare Life Sciences reported annual revenues of approximately $35 million. In 2012, the company received private equity funding from Linden Capital Partners, which facilitated the expansion of its product portfolio and R&D capabilities.

Pipeline Development

SeraCare continually expands its product portfolio to meet the evolving needs of the diagnostic industry. Recent additions include:

• SeraSure FBS: A PCR-tested BVD-negative fetal bovine serum for cell culture applications where BVD could interfere with downstream results.

• ACCURUN® 372 Series 600 HPV DNA Positive Control and ACCURUN® 872 HPV DNA Negative Control: Whole cell controls designed to challenge, troubleshoot, and improve HPV assay performance across multiple sample matrices.

• Cryo-T4 Human CD4+ T-cells, Cryo-T8 Human CD8+ T-cells, and Cryo-B Human CD19+ B-cells: New cellular products added to the AccuCell PBMC portfolio, valuable for studying autoimmune diseases, inflammatory diseases, oncology, and infectious diseases.

Technological Platform and Innovation

SeraCare's technological platforms are distinguished by:

• Seraseq Technology: Developed to create high-quality NGS reference materials, supporting the accurate and precise use of advanced diagnostic platforms such as NGS and digital PCR.

• AccuPlex Recombinant Viral Technology: Enables the development of custom recombinant controls and reference materials, enhancing assay validation and quality control.

• iQ™ NGS QC Management Software: A user-friendly software solution that simplifies the process for clinical labs to ensure optimal NGS assay performance and maintain compliance.

Leadership Team

SeraCare's leadership team comprises experienced professionals dedicated to advancing the company's mission:

• Charlie Mamrak: Appointed CEO in 2012 following the acquisition by Linden Capital Partners, bringing extensive experience in the diagnostics industry.

• Gregory A. Gould: Chief Financial Officer, overseeing the company's financial strategy and operations.

Competitor Profile

Market Insights and Dynamics

The diagnostic testing industry is characterized by rapid technological advancements and a growing emphasis on precision medicine. SeraCare operates in a competitive landscape with several key players offering similar products and services.

Competitor Analysis

Notable competitors include:

• BeiGene: A biotechnology company focused on discovering and developing oncology treatments.

• Jubilant Pharma: Specializes in the research, development, and manufacturing of radiopharmaceuticals and allergy therapy products.

• Genoskin: Provides ex vivo human skin models to the biotech, pharma, medtech, cosmetic, and chemical industries.

• Satellos Bioscience: Develops medicines to treat degenerative muscle diseases.

Additionally, companies such as Thermo Fisher Scientific and Bio-Rad Laboratories are considered competitors in the biotech and pharmaceuticals sector.

Strategic Collaborations and Partnerships

SeraCare has established strategic partnerships to enhance its product offerings and market reach. In 2013, the company acquired KPL, a provider of primary and secondary antibodies, reagents, and reference materials, thereby expanding its portfolio and strengthening its position in the diagnostics market.

Operational Insights

SeraCare's competitive advantages include:

• Comprehensive Product Portfolio: Offering a wide range of diagnostic quality controls, reagents, and biological materials.

• Technological Innovation: Developing proprietary technologies such as Seraseq and AccuPlex to support advanced diagnostic applications.

• Quality Assurance: Maintaining ISO 13485 certification, ensuring high standards in product development and manufacturing.

Strategic Opportunities and Future Directions

Looking ahead, SeraCare aims to:

• Expand Product Offerings: Continue developing innovative products to support emerging diagnostic technologies.

• Strengthen Global Presence: Enhance distribution networks and partnerships to reach a broader international market.

• Invest in R&D: Allocate resources to research and development to stay at the forefront of diagnostic advancements.

Contact Information

• Website: SeraCare Life Sciences

• LinkedIn: SeraCare Life Sciences

• Crunchbase: SeraCare Life Sciences